Table 1.
Recent clinical trials of mRNA-nanoparticle therapeutics against cancer.
| Organization | Cancer type | mRNA | Nanoparticle carrier | Administration route | Phase | NCT number |
|---|---|---|---|---|---|---|
| AstraZeneca | Solid tumors | MEDI 1191 (IL-12) | LNP | Intratumoral | I | NCT03946800 |
| BioNTech SE | Prostate cancer | W_pro1/BNT 112 (targeting 5 antigens) | Liposome | IV | I/II | NCT04382898 |
| Melanoma | BNT 122 (RO7198457) | Lipoplex | IV | II | NCT03815058 | |
| BNT 111 | Lipo-MERIT | IV | N/A | NCT02410733 | ||
| Colorectal cancer | BNT 122 (RO7198457) | Lipoplex | IV | II | NCT04486378 | |
| Solid tumor | CLDN6 | Lipoplex | IV | I/II | NCT04503278 | |
| Head and neck | BNT 113 | Lipoplex | IV | II | NCT04534205 | |
| Squamous cell | BNT 113 | Lipoplex | ID | I/II | NCT03418480 | |
| Carcinoma | ||||||
| Non-small cell lung cancer (NSCLC) | BNT 116 | Lipoplex | IV | I | NCT05142189 | |
| CureVac AG | NSCLC | mRNA CV9201 | RNActive® Protamine | ID | I/II | NCT00923312 |
| mRNA CV9202 | RNActive® Protamine | ID | I/II | NCT03164772 | ||
| Hormonal refractory prostate cancer | mRNA CV9301 | RNActive® Protamine | ID | I/II | NCT00831467 | |
| Merck Sharp & Dohme LLC | Carcinoma, NSCLC, neoplasms | mRNA-5671/V941 | LNP | IM | I | NCT03948763 |
| Moderna Therapeutics Inc. | Relapsed/refractory solid tumor malignancies or lymphoma | mRNA-2752 (OX40L, IL-23, IL-36γ) | LNP (lipid5, DSPC, cholesterol, PEG) | Intratumoral | I | NCT03739931 |
| mRNA-2416 (OX40L) | LNP | Intratumoral | I/II | NCT03323398 | ||
| Solid tumors | mRNA-4157 (personalized TAAs) | LNP | IM | I | NCT03313778 | |
| Melanoma | mRNA-4157 (personalized TAAs) | LNP | IV | II | NCT03897881 | |
| Pancreatic, colorectal neoplasms, NSCLC | mRNA-5671/Merck V941 | LNP | IM | I | NCT03948763 | |
| University Medical Center Groningen | Ovarian cancer | W_ova1 vaccine | Liposome | IV | I | NCT04163094 |
| University of Florida | Melanoma | Autologous total tumor mRNA | DOTAP liposome | IV | I | NCT05264974 |
| Adult glioblastoma | Autologous total tumor and full-length LAMP mRNA | DOTAP liposome | IV | I | NCT04573140 | |
| Changhai Hospital, Stemirna Therapeutics (layout) | Advanced esophageal | Personalized mRNA tumor vaccine | Lipopolyplex | SQ | N/A | NCT03468244 |
| Squamous carcinoma | ||||||
| Gastric adenocarcinoma | ||||||
| Pancreatic adenocarcinoma | ||||||
| Colorectal adenocarcinoma |